Pharmacoeconomic comparison of ziprasidone with other atypical oral antipsychotic agents in schizophrenia
DOI:
https://doi.org/10.7175/fe.v12i1.96Keywords:
Atypical oral antipsychotic agents, Ziprasidone, SchizophreniaAbstract
Objective: to comparatively investigate – by means of computer simulations – the economic cost and clinical outcomes of five atypical oral antipsychotic agents (ziprasidone, olanzapina, risperidone, paliperidone and aripiprazolo).Methods: a cyclical stochastic model representing patient evolution, taking into account main adverse reactions (akathisia, weight gain and extra-pyramidal ARs), drug efficacy on psychosis stabilization and probability of relapse, was developed. Ten different scenarios were compared, each starting with one of the considered antipsychotics, prescribed either at home or in a hospital setting. Switching to another medication was allowed until no untried drugs were available, in which case clozapine treatment or admission to a Psychiatric Therapeutic Rehabilitation Center were irreversibly assigned. Model inputs were probabilities of ARs, probabilities of stabilization and probabilities of destabilization (assumed equal for all); as well as costs attributable to drugs, hospitalization, outpatient care and costs adverse reactions in terms of concomitant medications. Sources for the inputs were the trials reported in the most recent literature (from the year 2000), selected based on the homogeneity of the observational period and antipsychotic dosage used.
Results: in each scenario, the hospitalization cost represented the highest component of the overall cost (approximately 67%). Assuming equal drug effectiveness, ziprasidone fared better than all other considered competitors, showing the lowest average annual costs per patient (and also the lowest average annual hospitalization costs) as well as the largest numbers of controlled months without adverse reactions, independently of the initial setting.
Conclusions: the most important determinant of total cost appears to be hospitalization, whose cost is about 600% higher than the medications cost. Medication effectiveness and tolerability remain however of utmost importance for the patients well being and reduction of hospitalization rate.
Downloads
Published
2011-11-21
How to Cite
Fagiolini, A., Matone, A., Gaz, C., Panunzi, S., & De Gaetano, A. (2011). Pharmacoeconomic comparison of ziprasidone with other atypical oral antipsychotic agents in schizophrenia. Farmeconomia. Health Economics and Therapeutic Pathways, 12(1), 29–40. https://doi.org/10.7175/fe.v12i1.96
Issue
Section
Review (Economic Analysis)
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)